Sammons, S. L., Topping, D. L., & Blackwell, K. L. (2017). HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles. Curr Cancer Drug Targets.
Chicago-stil citatSammons, Sarah L., Donna L. Topping, och Kimberly L. Blackwell. "HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles." Curr Cancer Drug Targets 2017.
MLA-referensSammons, Sarah L., Donna L. Topping, och Kimberly L. Blackwell. "HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles." Curr Cancer Drug Targets 2017.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.